CapsoVision Inc. (CV), a commercial-stage medical technology company, is scheduled to release fourth-quarter and full-year 2025 financial results on Thursday, March 26, 2026, after the close of the market.
The company develops AI-enabled imaging solutions for gastrointestinal (GI) disease detection and screening. Its flagship wire-free capsule endoscopy platform, CapsoCam Plus, offers 360° panoramic imaging with onboard video storage, enabling comprehensive small bowel visualization and detection of conditions such as obscure GI bleeding and Crohn's disease.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com